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Background: We performed this study to assess outcomes of patients with oropharyngeal cancer treated with
modern therapy approaches.
Methods: Demographics, treatments and outcomes of patients diagnosed with Stage 3- 4B squamous carcinoma
of the oropharynx, between 2000 – 2007 were tabulated and analyzed.
Results: The cohort consisted of 1046 patients. The 5- year actuarial overall survival, recurrence-free survival and
local-regional control rates for the entire cohort were 78%, 77% and 87% respectively. More advanced disease,
increasing T-stage and smoking were associated with higher rates of local-regional recurrence and poorer survival.
Conclusions: Patients with locally advanced oropharyngeal cancer have a relatively high survival rate. Patients’
demographics and primary tumor volume were very influential on these favorable outcomes. In particular, patients
with small primary tumors did very well even when treatment was not intensified with the addition of
chemotherapy.
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During the latter part of the 20th century, several changes
occurred in the management and epidemiology of head
and neck cancer. Numerous trials were conducted investi-
gating intensification of therapy. One avenue of investi-
gation was altered fractionation of radiation schedules.
Multiple trials demonstrated a benefit to mildly accelera-
ting radiation schedules, or hyperfractionating radiation
[1-3]. Incorporation of chemotherapy to improve disease
control and allow for organ preservation was studied
extensively during 1980 – 2000 [4]. Concomitant chemo-
therapy and radiation has become established as a stand-
ard of non-surgical care for patients with locally advanced
disease. Sequential induction chemotherapy followed by
definitive radiotherapy, with or without concomitant
chemotherapy, remains under study; however, there has* Correspondence: agarden@mdanderson.org
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reproduction in any medium, provided the orbeen FDA approval for use of docetaxel, cisplatin and
fluorouracil (TPF) as an induction regimen in selected
patients [5].
Intensity-modulated radiation therapy (IMRT) also was
developed during the last decade of the 20th century.
IMRT is a system of radiation treatment planning and de-
livery that allows for more optimal radiation dose distribu-
tions. Favorable early reports published in the first few
years of the past decade [6-8] led to the incorporation of
IMRT into many cooperative group trials, and there has
been a striking increase between 2000–2010 in the use of
IMRT as a routine therapy for head and neck cancer [9].
These changes in management have paralleled a change
in the epidemiology of head and neck cancer in the past 2
decades, and particularly oropharyngeal cancer. There has
been a dramatic increase in the incidence of oropharyngeal
cancer particularly among middle-aged white men [10].
With declining smoking prevalence over this timeframe,
the phenomenon of rising oropharyngeal cancer incidence
has been attributed to the prevalence of oropharyngealLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[11,12]. Retrospective series and, more recently, secondary
analyses of prospective clinical trials have demonstrated
better prognoses for patients with HPV positive disease
compared with similarly treated patients who are HPV
negative [13-15].
In tandem with the therapeutic advances described
above, we progressively intensified therapy for patients
with oropharyngeal carcinoma, though we often attempted
to use a risk based approach [16] that incorporated disease
volume and location rather than uniformly deliver identi-
cal therapy for all stage 3 and 4 patients. Previous reports
from our group suggested that patients with multiple
nodes or nodal disease in levels 3 and 4 had a greater risk
of developing distant disease [17]. In general, we favored
neoadjuvant therapy for these patients in attempt to re-
duce distant metastasis risk. Decisions for adding concur-
rent chemotherapy were based more often on T-category,
with higher staged patients treated with greater therapy in-
tensification. As our management approach evolved, we
observed demographic changes in our patients similar to
those occurring on a national level. This study was con-
ducted to assess our patients’ outcomes and determine
what factors were the most influential.Methods
The database maintained by the Department of Radiation
Oncology at The University of Texas M.D. Anderson Can-
cer Center (MDACC) was searched to identify patients
irradiated for oropharyngeal carcinoma (squamous cell,
poorly differentiated or undifferentiated, or not otherwise
specified) between the years 2000–2007. Our institutional
review board granted permission to conduct this retro-
spective study.
The search identified 1162 medical records. Patients
were excluded for the following reasons: distant metasta-
ses or concurrent malignancies (exclusive of a second
malignancy of the oropharynx) at the time of diagnosis
(16 patients), a previously treated malignancy of the head
and neck or previous radiation to the head or neck (8), a
history of any malignancy (excluding non-melanomatous
skin cancer) within two years of diagnosis (7), or treat-
ment with chemotherapy prior to staging at MDACC (8).
In addition 69 patients who did not meet the staging cri-
teria of interest (Stage 3- 4B), and 8 patients with poor
performance statuses, staged 4B, and treated with pallia-
tive intent were excluded. One thousand forty-six patients
formed the cohort for analysis.
Medical records were reviewed to assess patients’ demo-
graphic, clinical, radiologic and pathologic data. Based
upon the medical history at presentation and as described
previously [18] patients were classified as current smokers,
former smokers, or never-smokers. Smokers were furtherevaluated to assess if they quit smoking, or continued to
smoke during or subsequent to treatment.
Patients’ disease was staged according to the AJCC 2002
staging system [19]. Charts were reviewed to verify tumor
size and sites of invasion. Staging variables of interest
included T-category, N-category, and overall AJCC group
stage. Patients staged Tx were typically those seen post-
tonsillectomy and if the tumor size could not be deter-
mined after record review, these patients were staged T1
for the purpose of AJCC stage grouping in this analysis.
Those staged Nx were patients in whom a solitary node
was excised for diagnosis, and size could not be deter-
mined. These patients were coded as N1 for the purpose
of this analysis.
Chi-squared tests were used to compare proportions be-
tween subsets. The t-test was used for comparison of
means. The Kaplan-Meier method was used to calculate
actuarial curves. Time of diagnosis was used as time zero.
Comparisons between survival curves were made using
the log-rank test. Multivariate analysis was performed
using the Cox proportional model.
Our approach has been to perform neck dissection only
in patients with suspected residual disease following radi-
ation. During the years of this study reassessment princi-
pally consisted of physical examination and CT scan 6 to
8 weeks after radiation. Those patients with an obvious
residual mass were operated. Patients with questionable
residual disease had sonograms with aspiration performed
to try to resolve whether there was viable disease. Routine
use of positron-emission tomography had not become a
routine practice during the years of this study. Details of
our experience with regards to management of the neck
in an overlapping cohort has been recently described [20].
Patients who had neck dissections performed within
6 months of radiation for suspected residual disease were
not scored as having disease recurrence.
Results
Demographics and staging
Table 1 details the T and N stages of the 1046 patients.
Despite having “locally advanced” head and neck cancer,
62% of patients had T1-T2 tumors. Identification as hav-
ing stage 3-4B disease was often based on the presence of
nodal disease, as only 5% of patients were node negative.
Patients’ demographics, tumor sites and staging are
detailed in Table 2. Never smokers comprised 41% of the
cohort. Former smokers had quit 1 – 53 years prior to
diagnosis (median, 18 years). Among all smokers, the me-
dian and mean pack years were 30 and 34, though there
was a difference between former and current smokers,
with mean pack years of 27 and 45, respectively. Thirty-
one percent of former smokers, 56% of current smokers
who quit at diagnosis, and 78% of smokers who continued
to smoke had >30 pack year history at diagnosis (p < .001).
Table 1 T and N stages of 1046 patients with stage 3- 4b
oropharyngeal cancer
N-category Total
0 1 2a 2b 2c 3
T-category 1 0 81 69 118 26 22 316
2 0 59 47 134 53 31 324
3 37 30 6 81 46 19 219
4A 13 18 3 36 59 17 146
4B 7 4 0 10 10 10 41
Total 57 192 125 379 194 99 1046
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mary sites. Tonsil and base of tongue primary sites
accounted for only 85% of current smoking patients com-
pared with 94% and 96% for former and never smokers,
respectively (p < .001). There were also significant differ-
ences among the stages of the 3 smoking groups. The
overall group staging was different among the smoking
groups as Stage 4B was most common among current
smokers (p < .001). Never smokers had a greater propor-
tion of smaller primary tumors (71%, T1-2) compared with
former smokers (62%, T1-2), and current smokers (44%,
T1-T2). Differences in N-category among the 3 smoking
groups were not statistically significant, though the trends
observed were for never smokers to have a higher propor-
tion of N1-2c patients and current smokers to have a
higher proportion of N0 and N3 patients.
Nodal location correlated with nodal stage. Only 4% of
patients with stage N1-2a had nodes in levels 3 or 4
compared with 51% of patients staged N2b-2c and 82%
of patients staged N3.
The primary site of tumor also correlated with stage.
Only 26% of patients with non-tonsil, non –base of tongue
cancers had stage T1-or T2 disease. Limiting comparisons
to the tonsil and base of tongue, there were differences
between these 2 sites as well. Patients with base of tongue
cancer were more likely to present with T4 primaries
(20%) compared to those with tonsillar cancer (12%).
Stage N0 was more common among patients with non-
tonsil / non-base of tongue primaries (22%) than for those
with cancers of the tonsil (5%) or base of tongue (4%).
Stage N2c was also more common for patients with base
of tongue cancer (24%) than for patients with tonsillar
cancer (13%).
Therapy
All patients had their cases discussed at a weekly multi-
disciplinary clinic and recommendations for therapy as
well as assessment for treatment on protocol were made.
During these years, we had participated in numerous ther-
apy trials, and 210 patients in this cohort were treated on
trial. Among the trials were 4 RTOG trials [8,13,21,22], themultiinstitutional phase III cetuximab trial [23] and 2 in-
house phase I-II trials [16,24]. Final treatment decisions were
made with the patient and their physicians. Pre-therapy
gastrostomies were not mandated prior to therapy, and
gastrostomy placement during therapy was individualized
based on the clinical scenario.
IMRT was used to treat 69% of our patients. Figure 1
shows the use of IMRT over the years of study, as we
began to incorporate IMRT into our practice in 2000; by
2006, it was used exclusively for our patients. While IMRT
was more commonly used in never smokers, during the
early 2000s many patients with T3 and T4 tumors were
enrolled on studies not allowing the use of IMRT. Seven
hundred patients were treated with once daily fraction-
ation. The median dose was 70 Gy (2.2 – 75 Gy). Four-
teen patients (1%) received less than 60 Gy. Nine of these
14 patients chose to discontinue treatment, 2 had treat-
ment stopped due to toxicity and 3 died during therapy.
The median number of fractions was 33 (1 – 44). Ipsilat-
eral therapy was used to treat 66 patients (6%) with well-
lateralized tonsillar cancer.
Systemic therapy was used in 645 patients (62%). Con-
current therapy was delivered to 513 patients (49%). Cis-
platin was the most common concurrent drug (344
patients), followed by carboplatin (100 patients), and
cetuximab (74 patients); 103 patients were treated with
multidrug regimens. Two hundred forty-two (23%)
patients were treated with neoadjuvant chemotherapy.
All neoadjuvant regimens were platin and taxane based.
One hundred twenty-four patients received both neoad-
juvant and concurrent chemotherapy. There were no dif-
ferences between delivering either concurrent or
induction chemotherapy when grouped by smoking sta-
tus. There were differences in the use of chemotherapy
based on staging. The use of concurrent chemotherapy
increased incrementally with T-category, as 14%, 39%, 80%
and 90% of patients with T1,T2,T3,T4, respectively
received concurrent chemotherapy. Induction therapy was
more commonly used among patients with advanced
nodal disease, as 34% of patients with N2b – N3 disease
were treated with neoadjuvant therapy compared with only
5% of patients staged N0 – N2a. There was no difference
in the use of induction chemotherapy based on T-category,
as 23% and 23% of patients with T1-2 disease and T3-4
disease received neoadjuvant chemotherapy. Overall, 44%
of patients with T1-2 disease received chemotherapy com-
pared to 89% of patients with T3-4 disease.
Ninety-six patients had tonsillectomies prior to therapy.
All 96 presented with lymphadenopathy. Twenty-eight of
these 96 patients had tonsillectomies performed as part of
their diagnostic staging procedures at MDACC. The
remaining 68 presented to MDACC following tonsillec-
tomy. Only one of these 68 patients had a tonsillectomy
done as a therapeutic procedure for known malignancy.
Table 2 Patient demographics and treatment
All (N = 1046)
No. (%)
Current smokers
(N = 242) No. (%)
Former smokers
(N = 381) No. (%)
Never smokers
(N = 423) No. (%)
p- value
Age in years
Mean (range) 56.2 (28–87) 55.6 (35 – 80) 59.3 (36 – 87) 53.7 (28 – 81) .01
Median 55 55 58 53
Sex .725
Male 906 (87) 207 (86) 334 (88) 365 (86)
Female 140 (13) 35 (14) 47 (12) 58 (14)
Race <.001
White 930 (89) 197 (21) 353 (38) 380 (41)
Black 47 (5) 29 (62) 3 (6) 15 (32)
Hispanic 55 (5) 12 (22) 19 (35) 24 (44)
Other 14 (1) 5 (36) 6 (43) 3 (21)
Cigarette pack-year <.001
None 423 (42) 423 (100)
1 - 30 339 (32) 86 (36) 253 (69)
>30 265 (26) 153 (64) 112 (31)
Primary site <.001
Tonsil 460 (44) 111 (46) 171 (45) 178 (42)
Base of tongue 511 (49) 95 (39) 186 (49) 230 (54)
Other* 75 (7) 36 (15) 24 (6) 15 (4)
T-category <.001
1-2 640 (62) 107 (44) 235 (62) 298 (71)
3-4 406 (38) 135 (56) 146 (38) 125 (30)
N-category .07
0 57 (5) 20 (8) 22 (6) 15 (4)
1 -2a 317 (30) 63 (26) 120 (31) 134 (32)
2b – 2c 573 (55) 128 (53) 205 (54) 240 (57)
3 99 (9) 31 (13) 34 (9) 34 (8)
Stage .001
3 206 (20) 43 (18) 83 (22) 80 (19)
4A 707 (68) 149 (62) 257 (68) 30 (72)
4B 133 (13) 50 (21) 41 (11) 42 (10)
Treatment .176
XRT alone 415 (40) 83 (34) 158 (42) 175 (41)
CTXRT 389 (37) 102 (43) 146 (38) 141 (33)
Ind. CTX > XRT 118 (11) 29 (12) 35 (9) 53 (13)
Ind. CTX > CTXRT 124 (12) 28 (12) 42 (11) 54 (14)
Radiation technique <.001
IMRT 714 (69) 141 (58) 211 (69) 316 (75)
3D conformal 328 (31) 101 (42) 120 (31) 107 (25)
Radiation Fractionation .442
Once- daily 700 (67) 154 (64) 250 (66) 296 (70)
Altered fractionation 346 (33) 88 (36) 131 (34) 127 (30)
*Other primary sites: soft palate, 19 patients; pharyngeal wall, 34, NOS (not otherwise specified), 22.
XRT – Radiotherapy; CTXRT – concurrent chemoradiation; Ind. CTX – Induction chemotherapy.
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Figure 1 Number of patients treated with conventional
radiation techniques and intensity-modulated radiation (IMRT).
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disease, and 3 had more comprehensive surgery on their
primary tumor. Fifty-five patients had neck dissections
and 88 had excisional biopsies of nodal disease prior to
therapy. A total of 44 patients (4%) presented without ob-
vious disease at both the primary site and neck.
Post-radiation neck dissections were performed in 253
patients; 64 patients (25%) had pathologic residual disease





















The median follow-up time was 58 months (range, 1 –
130 months). Only 15 of 801 patients (2%) alive at last
contact had less than 2 years of follow-up. The actuarial
5-year overall survival rate was 78% (95% CI, 75 – 81%).
Overall, 234 patients had disease recurrence, resulting
in a 5-year recurrence free survival rate of 77% (95% CI,
74 – 80%). The 5-year local-regional control rate was 87%
(95% CI, 85 – 89%), as 135 patients had disease recur at
the primary site or in the neck (52 at the primary site, 35
in the neck, and 48 in both the primary and neck). The
5- year actuarial overall survival for patients with local-
regional recurrence was 22% (95% CI, 15 – 30%).
The 5-year distant recurrence rate in patients who did
not have local regional recurrence was 11% (95% CI,
9 – 13%).
Forty-five (5%) of patients with local regional control
had a gastrostomy at last follow-up. Five of these patients
also had tracheostomies. Increasing stage (both T and N),
altered fractionation, conventional radiation technique,and concurrent chemoradiation were all associated with an
increased rate of gastrostomy (Table 3, univariate analysis).
Analysis of variables of interest
Primary site, smoking status, T-category, and radiation
technique were all associated in multivariate analysis with
local-regional control (Table 4). The crude local regional
control rates for patients grouped by primary site were:
tonsil 92%, base of tongue 86%, and other sites 68%. The 3
other variables were strongly correlated with each other.
Eighty-one percent of patients with T1-2 disease were
treated with IMRT, compared with 49% of patients with
T3-4 disease; 75% of never smokers were treated with
IMRT compared with 58% of current smokers; and 70% of
never smokers had T1-2 disease, compared with 44% of
current smokers.
The 5-year local-regional control rates were 75%, 88%,
and 92% for current smokers, former smokers, and never
smokers, respectively (Figure 2a). Among current smo-
kers, the 5-year actuarial local regional control rates were
78% and 67% (p =.08) for those who quit smoking versus
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*multivariable analysis; XRT – Radiotherapy; CTXRT – concurrent
chemoradiation; Ind. CTX – Induction chemotherapy.
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years former smokers had quit and the number of pack-
year among all smokers were both tested as continuous
variables, only pack-year was significant. Evaluating smok-
ing intensity (pack-year number) as a categorical variable
(Figure 2b), the 5-year actuarial local-regional control
rates were: zero pack-year, 92%, 1 – 30 pack-year, 89%,
>30 pack year, 75% (p=.064 in multivariate analysis).
Among current smokers, a lower smoking intensity was
associated with quitting, as 44% of smokers who quit at
diagnosis had 1–30 pack-year history, compared with only
27% of those who continued to smoke.
The 5-year actuarial local-regional control rates for
patients grouped by T-category were 96%, 93%, 85%, 65%,
and 59% for stages T1, T2, T3, T4a and T4b, respectivelyFigure 2 Local-regional control rates stratified by smoking. a)
stratification by status; b) stratification by pack-year history.
Figure 4 Local-regional control rates stratified by use of
concurrent chemotherapy (CTX) with radiation and T-category.
T1-2, no CTX, n = 470; T1-2, CTX, n = 170; T3-4 no CTX, n = 63; T3-4
CTX, n=343.
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grouping, as well as for all paired comparisons except T1
vs. T2 and T4a vs. T4b.
The only treatment factor statistically significant for an
association with local-regional control, was radiation treat-
ment technique as those treated with IMRT had a 91%
5-year rate of local-regional control compared to 77% for
patients treated with conventional techniques. However,
significant confounding by T-stage exists. Subgrouping
patients by T-category, the differences in local-regional
control were only seen in patients staged T4, as those trea-
ted with IMRT had a 5-year control rate of 77% compared
to 51% for those treated with conventional techniques.
The use of concurrent chemotherapy was not associated
with improved local-regional control. However in sub-
group analysis, (Figure 4), patients with T3-4 disease who
were treated with concurrent chemotherapy had a 5-year
actuarial rate of local-regional control of 77% compared
with 63% for those who did not receive concurrent chemo-
therapy (p=.01). Amongst patients with T1-2 disease, the
5-year actuarial rate of local-regional control was 91% for
those treated with concurrent chemotherapy compared
with 95% for those who did not receive concurrent chemo-
therapy (p=.06). In pairwise comparisons of concurrent
single agent cisplatin, carboplatin and cetuximab, we did
not find statistically significant differences in local-regional
control.
N-category was not associated with local recurrence,
but was associated with regional recurrence. The 5-year
actuarial regional control rates were 96%, 90%, and 83%
for stages N0-2a, N2b-c and N3, respectively. In multivari-
ate analysis, disease recurrence in the neck (limited to
patients with local control) was associated with nodal
level, as regional control rates were progressively worse
for patients with disease in levels 2, 3, and 4, respectively.
We further explored the interactions of T1-2 disease
with N-category and chemotherapy on local-regionalFigure 3 Local-regional control rates stratified by T-category.control, dichotimizing N-category into N1-2a and N2b-3.
Thirty-nine (15%) T1-2, N1-2a patients, and 230 of T1-2,
N2b-3 patients (60%) received chemotherapy (Table 5).
No statistical improvement in local-regional control was
seen for any of the groups who received chemotherapy,
nor was any benefit seen when further subgrouped by in-
duction or concurrent delivery.
Analysis of distant failure restricted to patients with
local-regional control revealed a higher metastasis rate
seen with increasing age, higher T-category and lower
neck levels. The 5-year distant failure rates were 7%, 16%
and 25% for patients with disease in neck levels 2, 3 and 4,
respectively. The 5-year distant failure rate for node nega-
tive patients was 13%. The 5-year distant failure rates for
patients treated with and without induction chemotherapy
were 13% and 11%, respectively (p =.636). Further sub-
group analysis of patients staged N2b – 3 also showed no
difference in distant failure rates for patients treated with
and without induction chemotherapy (p = .642).
Multiple variables were statistically associated with sur-
vival (Table 4). N-category was associated with survival out-
comes, but not in an orderly pattern, as patients with N2a
disease had the best outcomes, and node negative patients
did not have a higher survival rate than patients who were
node positive. Current smokers, older patients, advanced
T-category, primary site not in the tonsil or base of tongue,
and the use of concurrent chemotherapy were associated
with decreasing survival. The 5-year survival rates for
patients treated with and without concurrent chemothe-
rapy were 71% and 85%, respectively. Among patients with
T1-T2 disease, the 5-year survival rates were 90% and 90%
(p =.42) for those treated with and without concurrent
chemotherapy, and for patients with T3-T4 disease the
5-year survival rates were 63% and 42% (p < .01) for those
treated with and without concurrent chemotherapy.
Table 5 Local-regional control in patients with T1-2 disease dichotomized by N-category
T1-2, N1-2a T1-2, N2b-c
Patient number 5-year local-regional control Patient number 5-year local-regional control
Treatment
XRT alone 217 98% 154 92%
CTXRT 32 90% 87 90%
Ind. CTX > XRT 3 100% 96 94%
Ind. CTX > CTXRT 4 100% 47 93%
XRT – Radiotherapy; CTXRT – concurrent chemoradiation; Ind. CTX – Induction chemotherapy.
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died of other causes. Death in these patients was asso-
ciated (p<.01) with pack-years, as the 5-year survival rates
for recurrence-free patients who were never smokers,
smoked 1–30 pack-years and smoked >30 pack-years were
95%, 95% and 83%, respectively.Discussion
The management of oropharyngeal cancer continues to
evolve with new developments in biology, technology, and
clinical trials. Our current series describes a cohort of over
1000 patients with stage 3 and 4 oropharynx cancer trea-
ted over the past decade. High rates of disease control
were achieved overall, though analysis of variables sug-
gests a range of prognoses dependent principally on fac-
tors at presentation, which likely reflect the HPV status of
these cancers [12]. However, it appears that treatment fac-
tors also influence outcomes, including the use of IMRT
and chemotherapy in certain subgroups.
HPV status has recently been recognized as a major
prognostic factor in outcomes of patients with oropharynx
cancer [13]. However, the patients in our cohort were
treated prior to routine testing for HPV (and p16), and
retrospective pathologic review of over 1000 samples,
many of which are from outside institutions was impracti-
cal for this review, and likely to result in a large amount of
missing data points.
Our cohort did consist of 423 never smokers, and it is
recognized that the vast majority of patients who are
never smokers present with HPV positive tumors [25].
The 5-year local-regional control rate for these never smo-
kers was 92% consistent with other reports on outcomes
of HPV positive tumors. Without HPV status, it is more
challenging to assess outcomes in HPV negative patients
from our data, particularly since any history of tobacco ex-
posure may confound the outcome of patients regardless
of HPV status. Former smokers appeared to have similar
outcomes to never smokers. This may be due to this co-
hort having a lesser intensity of smoking, but also, as
noted recently by RTOG, [25] there is a greater percentage
of HPV-positive tumors among former smokers, com-
pared with current smokers.Based on our past experiences, our general philosophy
has been to use a risk-based approach that principally
incorporates staging into our management algorithms. His-
torically our irradiated oropharyngeal cancer patients with
T1 -2 disease had high rates of local control, [17,26,27] and
patients who were node positive had high rates of regional
control [28]. Thus, our decision to treat patients with con-
current chemoradiation was principally reserved for those
patients with bulky primary disease (T3-4). Using this
approach, we observed a clear benefit for our patients with
T3-4 disease treated with concurrent chemoradiation.
However, despite more intensive therapy based on T-cat-
egory, primary tumor size and extent remained a strong
prognostic factor. Regardless of smoking status, patients
with more advanced disease had a greater probability of
local recurrence. More advanced T-category was also asso-
ciated with a higher likelihood of distant recurrence and
poorer survival.
Despite the absence of HPV stratification, our 357
patients with T1-2 disease treated with radiation without
concurrent chemotherapy had 95% and 90% 5-year local
regional control and overall survival rates. Current guide-
lines favor concurrent therapy for all stage 3 and 4 pa-
tients. The evidence for this strategy, is robust, but based
on numerous studies that included patients with the most
advanced disease. Particularly for patients with T1 disease,
data is sparse, as few randomized trials evaluating the role
of concurrent therapy included patients with low volume
disease [4]. The RTOG, for example, has excluded patients
with T1 disease in their definitive trials of locally advanced
head and neck cancer [2,13,21,22]. Prior to the routine use
of chemotherapy for head and neck cancer, many had been
critical of the AJCC and UICC stage grouping [29]; in par-
ticular these studies have demonstrated more favorable
prognoses for patients with T1 node positive disease com-
pared with other patients staged 3-4A. Thus, particularly
for T1 staged patients (who typically represent about one-
third of the oropharyngeal carcinoma population) we con-
tinue to favor radiation alone.
We could not demonstrate a benefit in outcome for
patients treated with induction therapy, but as described
above, the rates of distant disease have decreased sug-
gesting a benefit at least compared to historical controls.
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tive oropharyngeal carcinoma patients treated with radi-
ation only [17]. These 299 patients had T1-2 disease and
were treated without systemic therapy. In that report,
the overall distant recurrence rate in patients with local
regional control was 17%, compared with 11% for the en-
tire current cohort here, and 7% for those staged T1-2.
This observation is despite the current cohort having a
higher percentage of patients staged N2b or greater, but
is consistent with other recent reports of outcomes of
patients treated with chemo-radiation for oropharyngeal
cancer. Two principal differences between our earlier ex-
perience and the current series are that a greater percent
of patients in the current series are likely HPV positive
and the greater use of chemotherapy in the current experi-
ence. As many series describe similarities in distant metas-
tases rates between HPV positive and negative patients
[13,14], greater credence is given to the second hypothesis
that chemotherapy likely impacted outcomes favorably.
The retrospective nature of this study prohibits category
1 based-evidence, and retrospective studies are commonly
critiqued for inherent biases. We believe the magnitude of
the cohort size obviates some of the concerns regarding the
inferiority of a retrospective study. In particular, all 1046
patients were treated with radiation schedules designed for
curative intent. Only 8 patients (< 1%) were excluded for
being treated with palliative radiation schedules, and while
the patient population was extracted from a database of
irradiated patients, it was extremely rare for our multidis-
ciplinary team to treat patients without radiation.
While MDACC is a tertiary cancer center, the popula-
tion presented here is likely as representative of the gen-
eral population presenting with oropharynx cancer. We
did not include a comorbidity index of our patients, but
the population did include patients who had comorbidities
that sometimes either precluded the use of cisplatin, the
drug with the strongest evidence of efficacy, or chemo-
therapy in general, thus including patients often excluded
in phase 3 trials. Comorbidities, combined with biases of
patients and individuals within a large multidisciplinary
team impacted ultimate treatment decisions, and help ex-
plain that while we used a risk-based approach, still some
of our patients with T1 category received chemotherapy,
while 10% of our patients with T4-category did not receive
chemotherapy.
We also chose a relatively narrow time frame (2000 –
2007) for this study, though going further back in time
would have allowed us to expand the cohort significantly.
This decision was made as we wanted to establish a robust
trial with adequate follow-up (median, 58 months), but
still reflect on modern treatment paradigms. Despite this
goal, our series had great heterogeneity of therapy which
reflects on the controversies of management for this dis-
ease. The last 2 decades saw great interest in treatmentintensification to improve outcomes which ironically coin-
cided with the increase in HPV related disease which has
been demonstrated to be more chemotherapy and radi-
ation sensitive [13-15,30]. Thus some patients were trea-
ted with chemotherapy doublets and radiation, while
others received altered radiation fractionation. Favorable
reports on taxane based induction regimens [5] led to an
increased use of neoadjuvant chemotherapy, particularly
for our patients with advanced nodal disease, though we
frequently eliminated concurrent chemotherapy in these
patients. Additionally, we often did not use chemotherapy
in patients with small tumor burden despite having
‘advanced-staged’ disease. Radiation strategies changed,
and we integrated more conformal radiation into our prac-
tice through the use of IMRT, and increased our use of ip-
silateral radiation for selected patients with tonsillar cancer
[31]. Even with this heterogeneity of patients and treat-
ments, we report high rates of disease control and survival.
In conclusion, we describe a cohort of over 1000 oro-
pharyngeal cancer patients with stage 3-4B disease irra-
diated over an 8 year period. These patients were treated
in an era in which chemotherapy was becoming well inte-
grated into the management of advanced head and neck
cancer, and IMRT developed into the routine form of radi-
ation planning and delivery. While several trials have
demonstrated HPV positivity is associated with improved
prognosis, we believe T-category, a classic “biomarker”
remains paramount in treatment decision-making. Thus
we still advocate radiation alone often as therapy for
patients with low volume disease despite nominally being
categorized as having stage 3 or 4 disease. We also caution
against treatment deintensification for patients with T4
disease, even if biomarkers such as HPV status suggest a
more favorable prognosis. While smoking status is not a
consistent surrogate for HPV status, it is clear that never
smokers have excellent outcomes. Furthermore, current
smokers should be strongly encouraged, counseled, and
treated for cessation as an important augmentation to the
principal cancer treatment.
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